文献速递肿瘤 PET/CT

神经内分泌肿瘤患者中[18F]AlF-NOTA-TATE与[68Ga]Ga-DOTA-TATE PET/CT的头对头比较:一项前瞻性研究

Head-to-Head comparison of [18F]AlF-NOTA-TATE and [68Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors: a prospective study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-09-12

这项前瞻性研究纳入20例疑似或确诊神经内分泌肿瘤(NET)患者,在3天内先后接受[18F]AlF-NOTA-TATE(7.8±1.8 mCi)与[68Ga]Ga-DOTA-TATE(3.9±0.6 mCi)PET/CT,比较病灶检出率、SUVmax、靶本比(TBR)、辐射剂量与安全性。两种显像剂总体病灶检出率一致,但[18F]AlF-NOTA-TATE在肝转移、淋巴结转移和骨转移中摄取更高、TBR更优,作者认为其可能成为NET诊断的有前景的替代显像剂。

要点

  • 20例患者中13例确诊NET、4例影像阴性、3例非NET病灶,两种显像剂总体病灶检出率一致。
  • [18F]AlF-NOTA-TATE在肝转移(SUVmax 63.9±24.9 vs 37.2±6.2,P=0.009)、淋巴结转移(中位SUVmax 33.8 vs 22.4,P=0.021)和骨转移(SUVmax 112.9±20.7 vs 66.1±6.7,P<0.001)中摄取更高。
  • [18F]AlF-NOTA-TATE的TBR在肝脏病变(77.8±32.4 vs 57.3±17.6,P=0.040)和骨转移(135.2±28.6 vs 89.3±18.9,P=0.001)中优于[68Ga]Ga-DOTA-TATE;有效剂量0.021±0.007 mSv/MBq,脾脏吸收剂量最高(0.109±0.059 mGy/MBq)。

核心结论

  • [18F]AlF-NOTA-TATE对神经内分泌肿瘤的病灶检出率与[68Ga]Ga-DOTA-TATE相当,同时表现出更高的肿瘤摄取和更优的靶本比(TBR)。
  • 作者认为这些结果提示[18F]AlF-NOTA-TATE可能作为NET诊断的有前景的替代显像剂。

研究设计与样本

  • 前瞻性临床比较研究,纳入20例疑似或确诊神经内分泌肿瘤患者(中位年龄52岁)。
  • 所有患者在3天内先后接受[18F]AlF-NOTA-TATE(7.8±1.8 mCi)和[68Ga]Ga-DOTA-TATE(3.9±0.6 mCi)PET/CT显像。
  • [18F]AlF-NOTA-TATE采用自行研发的基于柱色谱的直接纯化技术自动合成,并严格遵循质量控制标准。
  • 图像分析评估病灶检出率、最大标准化摄取值(SUVmax)和靶本比(TBR),同时评估辐射剂量学和生物分布特征。
  • 试验注册:中国临床试验注册中心(ChiCTR2300072266),注册日期2023年6月8日。

主要发现

  • 20例患者中13例诊断为NET,4例影像学阴性,3例为非NET病灶。
  • 生物分布分析显示[18F]AlF-NOTA-TATE在垂体、脾等正常器官的生理性摄取高于[68Ga]Ga-DOTA-TATE,但在脑和血池中摄取较低。
  • [18F]AlF-NOTA-TATE与[68Ga]Ga-DOTA-TATE在胰腺、肝脏、淋巴结和骨转移中的总体病灶检出率一致。
  • [18F]AlF-NOTA-TATE在肝转移(SUVmax 63.9±24.9 vs 37.2±6.2,P=0.009)、淋巴结转移(中位SUVmax 33.8 vs 22.4,P=0.021)和骨转移(SUVmax 112.9±20.7 vs 66.1±6.7,P<0.001)中的摄取显著高于[68Ga]Ga-DOTA-TATE。
  • TBR方面,[18F]AlF-NOTA-TATE在肝脏病变(77.8±32.4 vs 57.3±17.6,P=0.040)和骨转移(135.2±28.6 vs 89.3±18.9,P=0.001)中优于[68Ga]Ga-DOTA-TATE。

关键数值与推荐

  • 肝转移SUVmax:[18F]AlF-NOTA-TATE 63.9±24.9 vs [68Ga]Ga-DOTA-TATE 37.2±6.2,P=0.009。
  • 淋巴结转移中位SUVmax:[18F]AlF-NOTA-TATE 33.8 vs [68Ga]Ga-DOTA-TATE 22.4,P=0.021。
  • 骨转移SUVmax:[18F]AlF-NOTA-TATE 112.9±20.7 vs [68Ga]Ga-DOTA-TATE 66.1±6.7,P<0.001。
  • 肝病变TBR:[18F]AlF-NOTA-TATE 77.8±32.4 vs [68Ga]Ga-DOTA-TATE 57.3±17.6,P=0.040。
  • 骨转移TBR:[18F]AlF-NOTA-TATE 135.2±28.6 vs [68Ga]Ga-DOTA-TATE 89.3±18.9,P=0.001;有效剂量0.021±0.007 mSv/MBq;脾脏吸收剂量最高(0.109±0.059 mGy/MBq)。

临床怎么用

  • 作者认为[18F]AlF-NOTA-TATE可能作为神经内分泌肿瘤诊断的有前景的替代显像剂。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: A prospective comparison was conducted between [¹⁸F]AlF-NOTA-TATE and the routinely used clinical imaging agent [⁶⁸Ga]Ga-DOTA-TATE in patients with neuroendocrine tumors (NETs) to evaluate diagnostic performance, pharmacokinetic characteristics, and safety. Additionally, the clinical potential of [¹⁸F]AlF-NOTA-TATE as an alternative imaging agent was explored. METHODS: [¹⁸F]AlF-NOTA-TATE was synthesized automatically using a self-developed direct purification technology based on column chromatography, with strict adherence to quality control standards. A clinical comparative study enrolled 20 patients with suspected or confirmed neuroendocrine tumors (NETs) (median age: 52 years). All patients underwent PET/CT imaging with both [¹⁸F]AlF-NOTA-TATE (7.8 ± 1.8 mCi) and [⁶⁸Ga]Ga-DOTA-TATE (3.9 ± 0.6 mCi) within a 3-day interval. Image analysis included evaluation of parameters such as lesion detection rate, maximum standardized uptake value (SUVmax), and tumor-to-background ratio (TBR). In parallel, radiation dosimetry and biodistribution characteristics were also assessed. RESULTS: Among the 20 patients, 13 were diagnosed with NETs, 4 exhibited negative imaging findings, and 3 had non-NET lesions. Biodistribution analysis revealed that [¹⁸F]AlF-NOTA-TATE showed higher physiological uptake in normal organs such as the pituitary gland and spleen compared to [⁶⁸Ga]Ga-DOTA-TATE, but lower uptake in the brain and blood pool. The overall lesion detection rates of [¹⁸F]AlF-NOTA-TATE and [68Ga]Ga-DOTA-TATE in pancreas, liver, lymph nodes and bone metastases were consistent; however, [¹⁸F]AlF-NOTA-TATE demonstrated significantly higher uptake in liver metastases (SUVmax: 63.9 ± 24.9 vs. 37.2 ± 6.2, P = 0.009), lymph node metastases (median SUVmax: 33.8 vs. 22.4, P = 0.021), and bone metastases (SUVmax: 112.9 ± 20.7 vs. 66.1 ± 6.7, P < 0.001). In terms of tumor-to-background ratio (TBR), [¹⁸F]AlF-NOTA-TATE also outperformed [⁶⁸Ga]Ga-DOTA-TATE for liver lesions (77.8 ± 32.4 vs. 57.3 ± 17.6, P = 0.040) and bone metastases (135.2 ± 28.6 vs. 89.3 ± 18.9, P = 0.001). Dosimetry analysis indicated an effective dose of 0.021 ± 0.007 mSv/MBq, with the spleen receiving the highest absorbed dose (0.109 ± 0.059 mGy/MBq), and confirmed good safety. CONCLUSION: [¹⁸F]AlF-NOTA-TATE demonstrated a comparable lesion detection rate to [⁶⁸Ga]Ga-DOTA-TATE for the diagnosis of neuroendocrine tumors (NETs), while exhibiting higher tumor uptake and superior tumor-to-background ratios (TBR). These results suggest that [¹⁸F]AlF-NOTA-TATE may serve as a promising alternative for the diagnosis of NETs. TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR2300072266), registered on 8 June 2023.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Liu H, Ma G, Wen H, et al. Head-to-Head comparison of [18F]AlF-NOTA-TATE and [68Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors: a prospective study. Eur J Nucl Med Mol Imaging. 2025. PMID: 40938396. doi:10.1007/s00259-025-07532-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。